Welcome to our dedicated page for Inovio Pharmaceu SEC filings (Ticker: INO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The INOVIO (Inovio Pharmaceuticals, Inc., NASDAQ: INO) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a biotechnology issuer focused on DNA medicines for HPV-related diseases, cancer, and infectious diseases, INOVIO uses SEC filings to report on financing activities, clinical and regulatory milestones, and its financial condition.
Investors can review Form 8-K current reports in which INOVIO discloses material events such as underwritten public offerings of common stock and warrants, entry into underwriting agreements, and the announcement of quarterly financial results. These filings detail terms of offerings, expected net proceeds, and the registration statements used, giving context to capital-raising transactions that support development of candidates like INO-3107.
Periodic reports such as Form 10-Q and Form 10-K (referenced in company press releases) provide broader information on research and development expenses, general and administrative costs, net loss, cash and investment balances, and risk factors related to clinical trials, regulatory pathways, and intellectual property. These documents help readers understand how INOVIO funds and manages its DNA medicines platform, including programs in RRP, DMAb technology, and DNA-encoded protein (DPROT) research.
On Stock Titan, INO filings are updated in near real time as they appear on EDGAR, and AI-powered summaries are available to explain complex sections in plain language. Users can quickly identify key elements in lengthy annual and quarterly reports, interpret the implications of financing-related 8-Ks, and locate references to registration statements and prospectus supplements. This page also surfaces information relevant to equity structure, such as inducement equity awards and warrant terms, helping investors track dilution and capital structure changes over time.
INOVIO PHARMACEUTICALS, INC. Chief Scientific Officer Laurent Humeau reported several equity award-related transactions on
In connection with these vesting and settlement events, the issuer withheld 2,064 and 3,034 common shares at a price of
INOVIO PHARMACEUTICALS, INC. CFO Peter Kies reported equity award activity on February 26, 2026. He acquired 5,010 and 10,634 shares of common stock through the vesting and settlement of previously granted restricted stock units, at a stated price of $0.00 per share.
To cover related tax withholding obligations, the issuer withheld 2,965 and 6,294 shares at $1.79 per share, recorded as tax-withholding dispositions rather than open-market sales. Following these transactions, Kies held common stock directly and also had an indirect holding of 375 shares attributed to his spouse.
INOVIO PHARMACEUTICALS, INC. Chief Executive Officer Jacqueline Elizabeth Shea reported vesting of restricted stock units and related tax share withholdings. On February 26, 2026, 18,632 and 28,401 restricted stock units converted into the same number of common shares, while 8,057 and 13,657 shares were withheld to cover tax obligations.
INOVIO PHARMACEUTICALS, INC. Chief Medical Officer Michael John Sumner reported vesting and settlement of previously granted restricted stock units into common stock. On February 26, 2026 he acquired 5,010 and 11,550 shares of common stock upon exercise or conversion of vested restricted stock units granted in 2024 and 2025, respectively. A total of 3,903 common shares were withheld by the company at a price of $1.79 per share to cover his tax obligations related to this vesting. Following these transactions, Sumner directly owned 30,507 shares of INOVIO common stock.
INOVIO PHARMACEUTICALS director David B. Weiner acquired 972 shares of common stock through an RSU conversion. On
These units were part of a 2,916‑unit grant made on
Inovio Pharmaceuticals, Inc. received an amended Schedule 13G/A showing that Alyeska Investment Group, Alyeska Fund GP and Anand Parekh beneficially own 4,000,000 shares of common stock, equal to 5.99% of the company. They report shared power to vote and dispose of these shares, held through warrants, and state the position is held in the ordinary course of business and not to influence control of Inovio.
The Vanguard Group filed an amended Schedule 13G reporting its beneficial ownership in Inovio Pharmaceuticals Inc As of the event date of 12/31/2025, Vanguard reported beneficial ownership of 3,315,579 shares of Inovio common stock, representing 4.96% of the class.
Vanguard reported no sole voting or dispositive power, with 422,301 shares subject to shared voting power and 3,315,579 shares subject to shared dispositive power. The firm states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Inovio.
The filing notes an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries or business divisions are expected to report beneficial ownership separately while pursuing the same investment strategies as before.
Inovio Pharmaceuticals, Inc. filed an amendment to its prospectus supplement for a previously registered offering of 14,285,715 shares of common stock together with Series A and Series B warrants, or related pre-funded warrants. The amendment updates the terms of the outstanding Series A Warrants by extending their expiration time to 5:00 p.m. New York City time on March 31, 2026, while leaving all other warrant terms unchanged.
The company’s common stock trades on the Nasdaq Capital Market under the symbol INO, and the closing sale price was $1.51 per share on January 26, 2026. The amendment is meant to be read together with the original prospectus and its prior supplements when evaluating an investment in these securities.
Inovio Pharmaceuticals, Inc. has amended its outstanding Series A warrants to extend their expiration. The warrants, originally set to expire on January 28, 2026, will now be exercisable until 5:00 p.m. New York City time on March 31, 2026. These Series A warrants were issued in Inovio’s July 2025 underwritten public offering and are exercisable for up to 13,564,268 shares of common stock, or pre-funded warrants in lieu of common stock. The exercise price is $1.75 per share of common stock, or $1.749 per pre-funded warrant. All other terms of the Series A warrants remain unchanged.
Inovio Pharmaceuticals entered an underwriting agreement for a public offering of 13,158,000 shares of common stock at $1.90 per share. The underwriters exercised in full their 30‑day option to buy up to 1,973,700 additional shares on the same terms. All shares are being sold by the company.
Including the option shares, net proceeds to Inovio are expected to be approximately $26.5 million after underwriting discounts and estimated expenses. The closing is expected on or about November 12, 2025, subject to customary conditions. The transaction is being conducted under an effective Form S‑3 shelf, supplemented by a prospectus filed pursuant to Rule 424(b).